New drug trial aims to tame dangerous gene mutation
NCT ID NCT07249840
First seen Jan 05, 2026 · Last updated May 22, 2026 · Updated 22 times
Summary
This early-stage study tests if the drug ropeginterferon is safe for people with a JAK2 gene mutation who have high-risk features but no blood cancer yet. Twelve adults will receive injections every 4 weeks and be monitored for side effects and changes in their mutation levels. The goal is to see if the drug can control the condition and prevent it from getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JAK2 MUTATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mass General Brigham
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.